Cargando…

Barriers towards effective pharmacovigilance systems of biosimilars in rheumatology: A Latin American survey

PURPOSE: This review summarises the current status of regulatory guidelines for the approval of biosimilars in Latin America and highlights the main barriers to effective pharmacovigilance in this region. We also report results from a survey of Latin American rheumatologists assessing their understa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Castañeda‐Hernández, Gilberto, Sandoval, Hugo, Coindreau, Javier, Rodriguez‐Davison, Luis Felipe, Pineda, Carlos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6771580/ https://www.ncbi.nlm.nih.gov/pubmed/31148288 http://dx.doi.org/10.1002/pds.4785

Ejemplares similares

Clinical and regulatory perspectives on biosimilar therapies and intended copies of biologics in rheumatology
por: Mysler, Eduardo, et al.
Publicado: (2016)

Biosimilars in rheumatology: what the clinician should know
por: Castañeda-Hernández, Gilberto, et al.
Publicado: (2015)

Switching Between Reference Biologics and Biosimilars for the Treatment of Rheumatology, Gastroenterology, and Dermatology Inflammatory Conditions: Considerations for the Clinician
por: Moots, Robert, et al.
Publicado: (2017)

Biosimilars in oncology and inflammatory diseases: current and future considerations for clinicians in Latin America
por: Scheinberg, Morton, et al.
Publicado: (2018)

Latin-American challenges and opportunities in rheumatology
por: Rocha, Francisco Airton Castro
Publicado: (2017)

Pharmacovigilance Considerations for Biosimilars in the USA
por: Grampp, Gustavo, et al.
Publicado: (2015)

The changing landscape of biosimilars in rheumatology
por: Dörner, Thomas, et al.
Publicado: (2016)

Biosimilars in rheumatology: understanding the rigor of their development
por: Goel, Niti, et al.
Publicado: (2017)

Practical Guidance on Biosimilars, With a Focus on Latin America: What Do Rheumatologists Need to Know?
por: Azevedo, Valderilio Feijó, et al.
Publicado: (2019)

Era of biosimilars in rheumatology: reshaping the healthcare environment
por: Smolen, Josef S, et al.
Publicado: (2019)

Biosimilar Oncology Drugs in Europe: Regulatory and Pharmacovigilance Considerations
por: Francescon, Sara, et al.
Publicado: (2016)

EU pharmacovigilance regulatory requirements of anticancer biosimilar monoclonal antibodies
por: Francescon, Sara, et al.
Publicado: (2018)

Pharmacovigilance of biosimilars - Why is it different from generics and innovator biologics?
por: Gupta, Ranjan
Publicado: (2020)

Pharmacovigilance of biosimilars – Why is it different from generics and innovator biologics?
por: Oza, B, et al.
Publicado: (2019)

Cost-Effectiveness of Early Treatment with Originator Biologics or Their Biosimilars After Methotrexate Failure in Patients with Established Rheumatoid Arthritis
por: Patel, Dipen, et al.
Publicado: (2019)

Biosimilars in rheumatology: A review of the evidence and their place in the treatment algorithm
por: Schulze-Koops, Hendrik, et al.
Publicado: (2017)

Biosimilars in rheumatology: recommendations for regulation and use in Middle Eastern countries
por: El Zorkany, Bassel, et al.
Publicado: (2018)

Safety Profile of Biologics Used in Rheumatology: An Italian Prospective Pharmacovigilance Study
por: Barbieri, Maria Antonietta, et al.
Publicado: (2020)

Latin American Journal of Orthopedics and Traumatology
por: Camanho, Gilberto Luis
Publicado: (2015)

Review of biologics, biosimilars, and intended copies in rheumatology, and current practice in Iraq
por: Al Ani, Nizar Abdulateef, et al.
Publicado: (2018)

The role of the Nocebo effect in the use of biosimilars in routine rheumatology clinical practice
por: Kravvariti, Evrydiki, et al.
Publicado: (2019)

Toward a Latin American Cancer Observatory
por: Cazap, Eduardo, et al.
Publicado: (2015)

Recommendations on how to ensure the safety and effectiveness of biosimilars in Latin America: a point of view
por: Pineda, Carlos, et al.
Publicado: (2015)

First Latin American clinical practice guidelines for the treatment of systemic lupus erythematosus: Latin American Group for the Study of Lupus (GLADEL, Grupo Latino Americano de Estudio del Lupus)–Pan-American League of Associations of Rheumatology (PANLAR)
por: Pons-Estel, Bernardo A, et al.
Publicado: (2018)

2018 Position Paper on Biosimilars of the Greek Rheumatology Society and Professional Association of Greek Rheumatologists
por: Patrikos, Dimos, et al.
Publicado: (2019)

Comparison of treatment retention of originator vs biosimilar products in clinical rheumatology practice in Sweden
por: Di Giuseppe, Daniela, et al.
Publicado: (2021)

Quality Comparison of Biosimilar and Copy Filgrastim Products with the Innovator Product
por: Halim, Liem Andhyk, et al.
Publicado: (2018)

Latin American Association for the Study of the Liver
por: Brahm, Javier, et al.
Publicado: (2016)

Assessment of Knowledge, Attitude and Barriers towards Pharmacovigilance among Physicians and Pharmacists of Abbottabad, Pakistan
por: Syed, Akash, et al.
Publicado: (2018)

Global excellence in rheumatology in Latin America: The case of systemic lupus erythematosus
por: Ugarte-Gil, Manuel F., et al.
Publicado: (2023)

Hip Fractures in the Elderly During the COVID-19 Pandemic: A Latin-American Perspective With a Minimum 90-Day Follow-Up
por: Zamora, Tomas, et al.
Publicado: (2021)

Assisted Reproductive Techniques in Latin America: The Latin American Registry, 2015
por: Zegers-Hochschild, Fernando, et al.
Publicado: (2019)

Assisted reproductive techniques in Latin America: The Latin American registry, 2016
por: Zegers-Hochschild, Fernando, et al.
Publicado: (2019)

Implementing a simple pharmacovigilance program to improve reporting of adverse events associated with biologic therapy in rheumatology: Preliminary results from the Calabria Biologics Pharmacovigilance Program (CBPP)
por: Palleria, Caterina, et al.
Publicado: (2018)

The road to biosimilars in rare diseases ‐ ongoing lessons from Gaucher disease
por: Drelichman, Guillermo, et al.
Publicado: (2019)

Overcoming Barriers to the Market Access of Biosimilars in the European Union: The Case of Biosimilar Monoclonal Antibodies
por: Moorkens, Evelien, et al.
Publicado: (2016)

Patterns of Tumor Necrosis Factor Inhibitor (TNFi) Biosimilar Use Across United States Rheumatology Practices
por: Bansback, Nick, et al.
Publicado: (2020)

Latin American classics.
Publicado: (1995)

Latin American Ballets/
por: Eduardo Mata

Latin american stories

Cannot write session to /tmp/vufind_sessions/sess_h1k3d7618u0tb6blmnsl8aksic